Blastomycosis Treatment Market Report 2026

The blastomycosis treatment market size has grown strongly in recent years. It will grow from $0.73 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to improved awareness of systemic fungal infections, availability of antifungal drug therapies, expansion of diagnostic laboratory services, increased clinical recognition of blastomycosis cases, growth of infectious disease treatment programs.

The blastomycosis treatment market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing focus on early and accurate diagnosis, rising development of improved antifungal formulations, expansion of specialized infectious disease care centers, growing use of personalized treatment approaches, increasing investment in fungal disease research. Major trends in the forecast period include increasing adoption of advanced diagnostic protocols, rising use of targeted antifungal therapies, expansion of therapeutic drug monitoring practices, growing focus on early disease detection, enhanced integration of clinical decision support tools.

The growing incidence of fungal diseases is anticipated to drive the growth of the blastomycosis treatment market in the coming years. Fungal diseases refer to infections caused by pathogenic fungi that can enter the body through inhalation, direct contact, or environmental exposure. The rising occurrence of fungal diseases is primarily driven by climate-related environmental changes, as increasing precipitation and flooding create moist, organic soil conditions that promote fungal spore proliferation and subsequent human exposure. The increasing prevalence of fungal infections boosts demand for effective treatment options, as early diagnosis and proper antifungal therapy are essential for preventing severe complications and reducing mortality. For example, in May 2025, according to the UK Health Security Agency, a UK-based government agency, bloodstream infections attributed to yeast increased by 4% in 2024 compared with 2023, rising from 2,170 to 2,247 reported cases. Therefore, the growing incidence of fungal diseases is driving the growth of the blastomycosis treatment market.

The increasing immunocompromised population is anticipated to drive the growth of the blastomycosis treatment market in the coming years. The immunocompromised population refers to individuals whose immune systems are weakened due to underlying diseases, genetic conditions, or medical treatments such as chemotherapy, immunosuppressive drugs, or organ transplantation. The immunocompromised population is rising due to improved survival of people with chronic conditions, coupled with the expanding use of immunosuppressive and immunomodulating therapies for autoimmune and inflammatory diseases. Blastomycosis treatment supports the immunocompromised population by providing effective antifungal therapy that controls severe and disseminated infections, reduces fungal burden, and prevents life-threatening complications in patients with weakened immune systems. For example, in September 2024, according to Infection & Chemotherapy (IC), a South Korea-based journal, as of December 2023, South Korea had a cumulative total of 19,001 individuals diagnosed with HIV, of whom 1,219 (6.4%) were women. In 2022 alone, 1,066 new HIV cases were identified, including 82 women (7.7%), comprising 35 Korean nationals and 47 foreign nationals. During the same year, the total number of Korean nationals living with HIV reached 15,880, with women accounting for 998 cases. Therefore, the increasing immunocompromised population is driving the growth of the blastomycosis treatment market.

Companies operating in the blastomycosis treatment market are focusing on developing advanced solutions, such as antifungal drug development, to gain improved treatment efficacy, enhanced safety profiles, and a stronger foothold in addressing unmet needs for severe systemic fungal infections. Antifungal drug development refers to the creation of antifungal therapies designed to improve upon existing treatments by enhancing efficacy, reducing toxicity, overcoming drug resistance, and offering better dosing, formulation, or delivery options. For example, in June 2024, Elion Therapeutics, a US-based biotechnology company, announced that SF001 is a next-generation polyene antifungal and a novel analog of amphotericin B, a drug long established as a first-line treatment for severe systemic fungal infections, including blastomycosis. While the press release specifically mentions invasive fungal infections such as aspergillosis, the mechanism of action of SF001 as an amphotericin B derivative designed to retain broad-spectrum antifungal activity while reducing toxicity makes it relevant to the treatment of blastomycosis as well. Because amphotericin B is effective against Blastomyces dermatitidis, a drug built on its structure and function, like SF001, is logically connected to blastomycosis therapy.

Major companies operating in the blastomycosis treatment market are Johnson & Johnson, Pfizer Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Astellas Pharma Inc., bioMérieux SA, Cipla Ltd., Lupin Limited, SCYNEXIS Inc., and F2G Ltd.

Tariffs are influencing the blastomycosis treatment market by increasing costs of imported antifungal medications, diagnostic reagents, laboratory equipment, and hospital-grade pharmaceutical supplies. Healthcare providers in North America and Europe are most affected due to reliance on imported drug formulations and diagnostic technologies, while developing regions face higher treatment costs and access constraints. These tariffs are contributing to higher therapy expenses and extended procurement cycles. However, they are also encouraging domestic pharmaceutical production, regional diagnostic capacity building, and improved local availability of antifungal treatment solutions.

The blastomycosis treatment market research report is one of a series of new reports that provides blastomycosis treatment market statistics, including blastomycosis treatment industry global market size, regional shares, competitors with a blastomycosis treatment market share, detailed blastomycosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the blastomycosis treatment industry. This blastomycosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blastomycosis treatment involves the complete medical management of blastomycosis, a systemic fungal infection caused by Blastomyces species, mainly using long-term antifungal medications such as itraconazole for mild to moderate infections and amphotericin B for severe, widespread, or life-threatening cases, based on organ involvement and patient immune status. It also includes organized clinical surveillance, supportive therapy, follow-up imaging and laboratory testing, and focused management of complications affecting the lungs, skin, bones, or central nervous system to achieve full disease clearance and reduce the risk of recurrence.

The primary treatment types of blastomycosis treatment include antifungal drugs and surgical intervention. Antifungal drugs refer to medications that inhibit the growth of Blastomyces dermatitidis, the fungus responsible for blastomycosis, to treat and manage the infection. These treatments are applied across anatomical sites including lung, bones, central nervous system, and other anatomical regions. They are available in dosages such as tablet, injection, capsule, and other dosage forms. They are administered via routes including intravenous, oral, and other methods of administration, and are utilized by end users including hospitals, outpatient clinics, and diagnostic laboratories.

The blastomycosis treatment market includes revenues earned by entities through clinical diagnosis and disease confirmation services, laboratory testing and fungal culture analysis, histopathological examination services, antifungal drug therapy management services, and therapeutic drug monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.